Download PDF

1. Company Snapshot

1.a. Company Description

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.


The company was formerly known as Aastrom Biosciences, Inc.Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on VCEL

Vericel Corporation's recent performance was negatively impacted by tepid growth in its MACI product revenue, which grew 21% to $239.5 million, despite a 23% growth in fourth-quarter revenue. The company's net income growth of 59% to $16.5 million was notable, but may not have met investor expectations. Analysts have a "Moderate Buy" consensus rating on the stock, with three hold recommendations and four buy recommendations (Marketbeat Ratings). The company's recent earnings release showed in-line quarterly earnings of $0.45 per share.

1.c. Company Highlights

2. Vericel Corporation's Strong Q4 2025 Results and Promising 2026 Outlook

Vericel Corporation reported a robust fourth quarter 2025 with record total revenue of $92.9 million, a 23% increase from the previous year, driven primarily by the strong performance of its MACI product. MACI revenue reached $84.1 million, representing a 23% year-over-year growth and a 51% sequential growth from the third quarter. The company's gross margin was nearly 80%, and the adjusted EBITDA margin was 40% for the quarter. For the full year 2025, total revenue was $276.3 million, with MACI revenue at $239.5 million, a 21% increase. The actual EPS for the quarter was $0.45, in line with analyst estimates. The company's financial performance was highlighted by a significant expansion in its sales force by 30% in the last couple of months, which is expected to drive further growth.

Publication Date: Mar -01

📋 Highlights
  • Record Q4 Revenue Growth:: Vericel reported $92.9M in Q4 2025 revenue, a 23% YoY increase, driven by MACI revenue of $84.1M (23% YoY, 51% sequential growth).
  • Strong Full-Year 2025 Performance:: Total revenue reached $276.3M, with MACI contributing $239.5M (21% YoY growth) and Burn Care $36.8M.
  • 2026 Revenue Guidance:: Projects $316–326M total revenue, with MACI expected to grow 20% to $280–286M and Burn Care at $36–40M.
  • Margin Adjustments:: Gross margin is projected to decline to 75% in 2026 from 79% in Q4 2025 due to new manufacturing costs, despite strong adjusted EBITDA of 40% in Q4.
  • Sales Force Expansion & Surgeon Training:: A 30% sales force increase and 1,000 trained surgeons for MACI Arthro drove volume growth, supporting 20%+ MACI franchise growth in 2026.

Guidance and Strategic Imperatives for 2026

For 2026, Vericel expects total revenue of $316 million to $326 million, with MACI revenue projected to be $280 million to $286 million. The company has outlined three strategic imperatives for 2026: capitalizing on the larger MACI sales force, leveraging MACI Arthro to drive growth in smaller cartilage defects, and advancing life cycle management initiatives. The guidance for MACI is around 20% growth, which is in line with analyst expectations. The company feels good about the start of the year, with MACI metrics being strong and Burn Care having a strong start as well. Analysts estimate next year's revenue growth at 18.0%, indicating a consistent growth trajectory.

Operational Highlights and Margin Expectations

The company has expanded its sales force and expects rep productivity to return to last year's level quickly. The new sales force expansion will increase the company's reach across the surgeon base and drive expansion of surgeons and deeper penetration in existing surgeons. Regarding gross margin, the company reported 79% in Q4 2025 but guided for 75% in 2026 due to additional costs associated with the new manufacturing facility in Burlington and depreciation. The company anticipates OpEx of approximately $220 million for the full year, with $55 million per quarter, mainly driven by the expansion of the sales force and incremental costs associated with the Ankle trial.

Valuation and Growth Prospects

With a P/E Ratio of 109.28 and an EV/EBITDA of 60.57, the market appears to have priced in significant growth expectations for Vericel Corporation. The company's ROE is 5.17%, and ROIC is 2.32%, indicating a decent return on equity but a relatively lower return on invested capital. The Net Debt / EBITDA ratio is -0.13, highlighting the company's net cash position. As Vericel looks forward to sustained high revenue growth and profitability in 2026 and beyond, driven by MACI and Burn Care, the current valuation metrics suggest that the stock may be priced for high expectations, and investors will be watching closely to see if the company can deliver on its growth promises.

3. NewsRoom

Card image cap

Intech Investment Management LLC Decreases Stock Holdings in Vericel Corporation $VCEL

Mar -09

Source: defenseworld.net

Card image cap

Vericel Corporation (VCEL) Matches Q4 Earnings Estimates

Feb -26

Source: zacks.com

Card image cap

Vericel Corporation (VCEL) Q4 2025 Earnings Call Transcript

Feb -26

Source: seekingalpha.com

Card image cap

Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb -26

Source: globenewswire.com

Card image cap

Vericel Corporation (NASDAQ:VCEL) Receives Average Recommendation of “Moderate Buy” from Analysts

Jan -18

Source: defenseworld.net

Card image cap

Vericel Corporation (VCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan -14

Source: seekingalpha.com

Card image cap

Vericel Announces Preliminary 2025 Financial Results and Business Updates

Jan -13

Source: globenewswire.com

Card image cap

Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026

Jan -06

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.02%)

6. Segments

MACI

Expected Growth: 8.5%

MACI's 8.5% growth is driven by increasing adoption in cartilage repair procedures, expanding orthopedic surgeon network, and rising demand for minimally invasive treatments. Additionally, Vericel's strategic partnerships, investments in sales and marketing, and growing awareness of cartilage defects among patients and physicians contribute to the segment's growth.

Epicel

Expected Growth: 11.7%

Epicel's 11.7% growth driven by increasing adoption in burn care centers, expansion into new markets, and rising demand for autologous skin substitute treatments. Strong sales force execution, strategic partnerships, and favorable reimbursement environment also contribute to growth.

NexoBrid

Expected Growth: 9.33%

NexoBrid's 9.33% growth is driven by increasing adoption in burn care, strong sales force execution, and expanding hospital penetration. Additionally, growing awareness of the benefits of debridement in wound care, and the product's unique enzymatic mechanism of action, contribute to its rising demand.

7. Detailed Products

MACI

MACI (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) is a surgical implant used to repair damaged or diseased cartilage in the knee.

Epicel

Epicel (Cultured Epithelial Autografts) is a permanent skin substitute used to treat severe burns, wounds, and skin defects.

8. Vericel Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Vericel Corporation's products are highly specialized and there are limited substitutes available in the market, reducing the threat of substitutes.

Bargaining Power Of Customers

Vericel Corporation's customers are primarily hospitals and clinics, which have limited bargaining power due to the specialized nature of the company's products.

Bargaining Power Of Suppliers

Vericel Corporation relies on a limited number of suppliers for raw materials, which gives them some bargaining power, but the company's specialized products reduce the suppliers' negotiating power.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise, making it difficult for new entrants to compete with Vericel Corporation.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with several established players competing for market share, which increases the intensity of rivalry for Vericel Corporation.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 28.04%
Debt Cost 3.95%
Equity Weight 71.96%
Equity Cost 12.63%
WACC 10.19%
Leverage 38.97%

11. Quality Control: Vericel Corporation passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Revance Therapeutics

A-Score: 5.1/10

Value: 8.6

Growth: 6.1

Quality: 6.2

Yield: 0.0

Momentum: 6.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
TRACON Pharmaceuticals

A-Score: 4.9/10

Value: 10.0

Growth: 7.0

Quality: 6.2

Yield: 0.0

Momentum: 6.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Matinas BioPharma

A-Score: 4.1/10

Value: 8.4

Growth: 4.2

Quality: 3.4

Yield: 0.0

Momentum: 8.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Vericel

A-Score: 3.4/10

Value: 0.7

Growth: 7.9

Quality: 5.9

Yield: 0.0

Momentum: 2.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Arvinas

A-Score: 3.4/10

Value: 7.9

Growth: 4.4

Quality: 4.3

Yield: 0.0

Momentum: 1.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
C4 Therapeutics

A-Score: 2.9/10

Value: 7.8

Growth: 2.4

Quality: 4.3

Yield: 0.0

Momentum: 2.5

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

32.11$

Current Price

32.11$

Potential

-0.00%

Expected Cash-Flows